Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The PepGen logo on a map of the USA. A plane is flying from the PepGen logo to where the city of Boston is marked on the map.

One of the first companies to move into the BioEscalator when it opened its doors, PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, has relocated to Boston, USA.

 

PepGen raised $112.5M in August of 2021, and the funding allowed the expansion of PepGen's team in its headquarters in Boston. The new PepGen headquarters will manage late-stage pre-clinical testing and clinical and regulatory functions.

 

Caroline Godfrey, co-founder and previous CEO of PepGen, has recently been appointed to the company's scientific advisory board. She will continue contributing to PepGen's science as the company continues to expand in its new location.

 

PepGen's website